NCT03233763

Brief Summary

Ongoing laboratory work into the pathology of Leukaemia:

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

April 24, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 31, 2017

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

July 31, 2017

Status Verified

July 1, 2017

Enrollment Period

3.8 years

First QC Date

January 18, 2017

Last Update Submit

July 26, 2017

Conditions

Leukemia

Outcome Measures

Primary Outcomes (1)

  • Pathology of Leukaemia cells

    Pathology of Leukaemia cells

    15 years

Interventions

Bone Marrow AspiratePROCEDURE

Diagnostic Bone Marrow aspirate

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This is an exploratory laboratory study using stored tissue where consent has already been given.

You may qualify if:

  • \& Over Diagnosis of AML Generic Research consent given

You may not qualify if:

  • Under 18 No generic research consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Haematology, the Royal Marsden NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Bone Marrow and blood

MeSH Terms

Conditions

Leukemia

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • David Taussig

    Royal Marsden NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Leonora Conneely

CONTACT

0208 661 3018leonora.conneely@rmh.nhs.uk

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2017

First Posted

July 31, 2017

Study Start

April 24, 2017

Primary Completion

February 1, 2021

Study Completion

February 1, 2021

Last Updated

July 31, 2017

Record last verified: 2017-07

Data Sharing

IPD Sharing
Will share

Access to patient tissue is via formal request to the Sponsor

Locations

GB(1)